All In Biotech

Drug Trial Radar · NCT01580891

Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis

Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis.

Last checked: Nov 20, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,053 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,053

Actual

Start

May 2012

Primary completion

Mar 2013

Study completion Jul 2013

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream (Merz Pharmaceuticals) and placebo in patients with tinea pedis and to show the superiority of the active treatments over placebo when dosed once a day for 28 days.

Conditions

  • Tinea Pedis

Interventions

  • Naftifine HCl Cream 1%Drug

    Naftifine HCl Cream 1% applied topically once a day for 28 days.

  • Naftin® (Naftifine HCl) Cream 1%Drug

    Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.

  • Placebo topical creamDrug

    Placebo topical cream applied topically once a day for 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic CureTime frame: 42 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.